Product Showcase
Explore our comprehensive portfolio of pharmaceutical products
APIs
Irbesartan
Therapy
: Cardiometabolic diseases
Target
: AT1
CAS
: 138402-11-6
MF
: C25H28N6O
MW
: 428.53
Metoprolol Succinate
Therapy
: Cardiometabolic diseases
Target
: ADRB1
CAS
: 98418-47-4
MF
: 2C15H25NO3•C4H6O4
MW
: 652.8
Metoprolol Tartrate
Therapy
: Cardiometabolic diseases
Target
: β-adrenoceptors
CAS
: 56392-17-7
MF
: 2C15H25NO3•C4H6O6
MW
: 684.8
Clopidogrel Bisulfate
Therapy
: Cardiometabolic diseases
Target
: P2RY12
CAS
: 120202-66-6
MF
: C16H16ClNO2S•H2SO4
MW
: 419.9
Dabigatran Etexilate Mesylate
Therapy
: Cardiometabolic diseases
Target
: PT
CAS
: 872728-81-9
MF
: C34H41N7O5•CH4O3S
MW
: 723.84
Candesartan Cilexetil
Therapy
: Cardiometabolic diseases
Target
: AT1
CAS
: 145040-37-5
MF
: C33H34N6O6
MW
: 610.67
Captopril
Therapy
: Cardiometabolic diseases
Target
: ACE
CAS
: 62571-86-2
MF
: C9H15NO3S
MW
: 217.29
Enalapril Maleate
Therapy
: Cardiometabolic diseases
Target
: ACE
CAS
: 76095-16-4
MF
: C20H28N2O5•C4H4O4
MW
: 492.5
Lisinopril
Therapy
: Cardiometabolic diseases
Target
: ACE
CAS
: 76547-98-3
MF
: C21H31N3O5
MW
: 405.49
Losartan Potassium
Therapy
: Cardiometabolic diseases
Target
: AT1
CAS
: 124750-99-8
MF
: C22H23ClKN6O
MW
: 462.01
Torasemide
Therapy
: Cardiometabolic diseases
Target
: NKCC2
CAS
: 56211-40-6
MF
: C16H20N4O3S
MW
: 348.42
Valsartan
Therapy
: Cardiometabolic diseases
Target
: AT1
CAS
: 137862-53-4
MF
: C24H29N5O3
MW
: 435.52
Ramipril
Therapy
: Cardiometabolic diseases
Target
: ACE
CAS
: 87333-19-5
MF
: C23H32N2O5
MW
: 416.51
Linagliptin
Therapy
: Cardiometabolic diseases
Target
: DPP4
CAS
: 668270-12-0
MF
: C25H28N8O2
MW
: 472.54
Nebivolol
Therapy
: Cardiometabolic diseases
Target
: ADRB1
CAS
: 99200-09-6
MF
: C22H25F2NO4
MW
: 405.43
Olmesartan Medoxomil
Therapy
: Cardiometabolic diseases
Target
: AT1
CAS
: 144689-63-4
MF
: C29H30N6O6
MW
: 558.59
Perindopril Erbumine
Therapy
: Cardiometabolic diseases
Target
: ACE
CAS
: 107133-36-8
MF
: C23H43N3O5
MW
: 441.61
Quinapril Hydrochloride
Therapy
: Cardiometabolic diseases
Target
: ACE
CAS
: 82586-55-8
MF
: C25H31ClN2O5
MW
: 474.98
Ranolazine
Therapy
: Cardiometabolic diseases
Target
: Nav1.5
CAS
: 95635-55-5
MF
: C24H33N3O4
MW
: 427.54
Rivaroxaban
Therapy
: Cardiometabolic diseases
Target
: F10
CAS
: 366789-02-8
MF
: C19H18ClN3O5S
MW
: 435.88
Sitagliptin
Therapy
: Cardiometabolic diseases
Target
: DPP4
CAS
: 486460-32-6
MF
: C16H15F6N5O
MW
: 407.31
Telmisartan
Therapy
: Cardiometabolic diseases
Target
: AT1
CAS
: 144701-48-4
MF
: C33H30N4O2
MW
: 514.62
Vildagliptin
Therapy
: Cardiometabolic diseases
Target
: DPP4
CAS
: 274901-16-5
MF
: C17H25N3O2
MW
: 303.4
Carvedilol
Therapy
: Cardiometabolic diseases
Target
: VDCCs;β-adrenoceptors;ADRA1
CAS
: 72956-09-3
MF
: C24H26N2O4
MW
: 406.47
Edoxaban
Therapy
: Cardiometabolic diseases
Target
: F10
CAS
: 480449-70-5
MF
: C24H30ClN7O4S
MW
: 548.06
Ambrisentan
Therapy
: Cardiometabolic diseases
Target
: ETAR
CAS
: 177036-94-1
MF
: C22H22N2O4
MW
: 378.42
Apixaban
Therapy
: Cardiometabolic diseases
Target
: F10
CAS
: 503612-47-3
MF
: C25H25N5O4
MW
: 459.5
Benazepril Hydrochloride
Therapy
: Cardiometabolic diseases
Target
: ACE
CAS
: 86541-74-4
MF
: C24H29ClN2O5
MW
: 460.95
Canagliflozin
Therapy
: Cardiometabolic diseases
Target
: SGLT2
CAS
: 842133-18-0
MF
: C24H25FO5S
MW
: 444.52
Dabigatran Etexilate
Therapy
: Cardiometabolic diseases
Target
: PT
CAS
: 211915-06-9
MF
: C34H41N7O5
MW
: 627.73
Dapagliflozin
Therapy
: Cardiometabolic diseases
Target
: MR;SGLT2
CAS
: 461432-26-8
MF
: C21H25ClO6
MW
: 408.88
Empagliflozin
Therapy
: Cardiometabolic diseases
Target
: SGLT2
CAS
: 864070-44-0
MF
: C23H27ClO7
MW
: 450.91
Eprosartan Mesylate
Therapy
: Cardiometabolic diseases
Target
: AT1
CAS
: 144143-96-4
MF
: C24H28N2O7S2
MW
: 520.62
Fosinopril Sodium
Therapy
: Cardiometabolic diseases
Target
: ACE
CAS
: 88889-14-9
MF
: C30H46NNaO7P
MW
: 586.65
Dobutamine Hydrochloride
Therapy
: Cardiometabolic diseases
Target
: Adrenoceptors
CAS
: 49745-95-1
MF
: C18H24ClNO3
MW
: 337.84
Eptifibatide
Therapy
: Cardiometabolic diseases
Target
: GP IIb/IIIa
CAS
: 188627-80-7
MF
: C35H49N11O9S2
MW
: 831.97
Glimepiride
Therapy
: Cardiometabolic diseases
Target
: SUR;KATP channels
CAS
: 93479-97-1
MF
: C24H34N4O5S
MW
: 490.62
Isradipine
Therapy
: Cardiometabolic diseases
Target
: Voltage-gated L-type calcium channel
CAS
: 75695-93-1
MF
: C19H21N3O5
MW
: 371.39
Lacidipine
Therapy
: Cardiometabolic diseases
Target
: VDCCs
CAS
: 103890-78-4
MF
: C26H33NO6
MW
: 455.54
Lercanidipine
Therapy
: Cardiometabolic diseases
Target
: VDCCs
CAS
: 100427-26-7
MF
: C36H41N3O6
MW
: 611.73
Metformin Hydrochloride
Therapy
: Cardiometabolic diseases
Target
: PRKAB1
CAS
: 1115-70-4
MF
: C4H12ClN5
MW
: 165.62
Pentoxifylline
Therapy
: Cardiometabolic diseases
Target
:
CAS
: 6493-05-6
MF
: C13H18N4O3
MW
: 278.31
Pioglitazone
Therapy
: Cardiometabolic diseases
Target
:
CAS
: 111025-46-8
MF
: C19H20N2O3S
MW
: 356.44
Rosiglitazone Maleate
Therapy
: Cardiometabolic diseases
Target
:
CAS
: 155141-29-0
MF
: C22H23N3O7S
MW
: 473.5
Dopamine HCl
Therapy
: Cardiometabolic diseases
Target
:
CAS
: 62-31-7
MF
: C8H12ClNO2
MW
: 189.64
Amlodipine Besylate
Therapy
: Cardiometabolic diseases
Target
: VDCCs
CAS
: 111470-99-6
MF
: C26H31ClN2O8S
MW
: 567.05094
Atorvastatin Calcium
Therapy
: Cardiometabolic diseases
Target
: HMGCR
CAS
: 134523-03-8
MF
: C33H37CaFN2O5
MW
: 600.74
Bempedoic acid
Therapy
: Cardiometabolic diseases
Target
: ACLY
CAS
: 738606-46-7
MF
: C19H36O5
MW
: 344.49